| Literature DB >> 34801630 |
Maria Reig1, Alejandro Forner2, Jordi Rimola3, Joana Ferrer-Fàbrega4, Marta Burrel5, Ángeles Garcia-Criado3, Robin K Kelley6, Peter R Galle7, Vincenzo Mazzaferro8, Riad Salem9, Bruno Sangro10, Amit G Singal11, Arndt Vogel12, Josep Fuster13, Carmen Ayuso14, Jordi Bruix15.
Abstract
There have been major advances in the armamentarium for hepatocellular carcinoma (HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and treatment strategy published in 2018. Whilst there have been advances in all areas, we will focus on those that have led to a change in strategy and we will discuss why, despite being encouraging, data for select interventions are still too immature for them to be incorporated into an evidence-based model for clinicians and researchers. Finally, we describe the critical insight and expert knowledge that are required to make clinical decisions for individual patients, considering all of the parameters that must be considered to deliver personalised clinical management.Entities:
Keywords: AFP; ALBI score; BCLC; HCC; TARE; ablation; liver transplantation TACE; surgery; survival; systemic treatment
Mesh：
Year: 2021 PMID： 34801630 PMCID： PMC8866082 DOI： 10.1016/j.jhep.2021.11.018
Source DB: PubMed Journal: J Hepatol ISSN： 0168-8278 Impact factor: 30.083